Eyenovia, Inc, a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone917-289-1117
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date8/13/2019 (Estimated)
OptionableNot Optionable
Eyenovia (NASDAQ:EYEN) Frequently Asked Questions
What is Eyenovia's stock symbol?
Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."
How were Eyenovia's earnings last quarter?
Eyenovia Inc (NASDAQ:EYEN) announced its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.50) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.51) by $0.01. View Eyenovia's Earnings History.
When is Eyenovia's next earnings date?
What price target have analysts set for EYEN?
2 brokers have issued twelve-month target prices for Eyenovia's stock. Their forecasts range from $9.00 to $14.00. On average, they anticipate Eyenovia's stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 260.5% from the stock's current price. View Analyst Price Targets for Eyenovia.
What is the consensus analysts' recommendation for Eyenovia?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyenovia.
What are Wall Street analysts saying about Eyenovia stock?
Here are some recent quotes from research analysts about Eyenovia stock:
- 1. According to Zacks Investment Research, "Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc. is based in New York. " (6/25/2019)
- 2. HC Wainwright analysts commented, "Our price target is derived from a market value of the firm at $240M, which includes a discounted cash flow-based asset value for all four micro-dosing products, with a 15% discount rate and 1% terminal growth rate. Probabilities of success assigned are 80%, 75%, 55% and 45% for MicroPine, respectively." (2/14/2019)
Has Eyenovia been receiving favorable news coverage?
News stories about EYEN stock have trended somewhat positive on Monday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Eyenovia earned a news sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Eyenovia.
Are investors shorting Eyenovia?
Eyenovia saw a increase in short interest in June. As of June 30th, there was short interest totalling 135,700 shares, an increase of 10.5% from the May 30th total of 122,800 shares. Based on an average daily trading volume, of 52,800 shares, the short-interest ratio is presently 2.6 days. Currently, 2.2% of the company's shares are sold short. View Eyenovia's Current Options Chain.
Who are some of Eyenovia's key competitors?
Some companies that are related to Eyenovia include Marinus Pharmaceuticals (MRNS), Aeglea Bio Therapeutics (AGLE), Five Prime Therapeutics (FPRX), MannKind (MNKD), Mersana Therapeutics (MRSN), Chiasma (CHMA), Cerecor (CERC), Edge Therapeutics (EDGE), Ocular Therapeutix (OCUL), Affimed (AFMD), Harrow Health (HROW), Kala Pharmaceuticals (KALA), Chimerix (CMRX), Sol Gel Technologies (SLGL) and Osmotica Pharmaceuticals (OSMT).
What other stocks do shareholders of Eyenovia own?
Who are Eyenovia's key executives?
Eyenovia's management team includes the folowing people:
- Dr. Tsontcho Ianchulev M.P.H., M.D., MPH, CEO, Chief Medical Officer & Director (Age 46)
- Ms. Jennifer Clasby, VP of Clinical Operations (Age 65)
- Mr. Luke Clauson, VP of R&D (Age 40)
- Mr. John P. Gandolfo, CFO & Sec. (Age 58)
- Mr. Michael M. Rowe, VP of Marketing
When did Eyenovia IPO?
(EYEN) raised $30 million in an initial public offering (IPO) on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners served as the underwriters for the IPO.
How do I buy shares of Eyenovia?
Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Eyenovia's stock price today?
One share of EYEN stock can currently be purchased for approximately $3.19.
How big of a company is Eyenovia?
What is Eyenovia's official website?
How can I contact Eyenovia?
Eyenovia's mailing address is 295 Madison Avenue Suite 2400, New York NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected]
MarketBeat Community Rating for Eyenovia (NASDAQ EYEN)
MarketBeat's community ratings are surveys of what our community members think about Eyenovia and other stocks. Vote "Outperform" if you believe EYEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EYEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
